drugset / Trial / NCT01550900

Prospective Trial of Metformin - Chemoprevention Role

NCT01550900 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical research study is to learn if metformin extended release (ER) can prevent colonic adenomas from becoming cancerous. Metformin ER will be compared to a placebo. Metformin ER is designed to block a protein in tumor cells that is important in tumor growth and blood vessel development. This may cause cell death or reduce the spread of the disease. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Timeline

Start
2013-07
Primary completion
2020-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg Oral

Indications